Zentalis Pharmaceuticals Inc
ZNTL1.390USD
+0.050+3.73%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
100.01MCap. mercado
PérdidaP/E TTM
Más Datos de Zentalis Pharmaceuticals Inc Compañía
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Información de la empresa
Símbolo de cotizaciónZNTL
Nombre de la empresaZentalis Pharmaceuticals Inc
Fecha de salida a bolsaApr 03, 2020
Director ejecutivoMs. Julie Eastland
Número de empleados166
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 03
Dirección10275 Science Center Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121
Teléfono18582634333
Sitio Webhttps://www.zentalis.com/
Símbolo de cotizaciónZNTL
Fecha de salida a bolsaApr 03, 2020
Director ejecutivoMs. Julie Eastland
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 23 de jul
Actualizado: mié., 23 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
Accionistas
Accionistas
Proporción
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
33.53%
Investment Advisor
20.08%
Hedge Fund
18.52%
Individual Investor
12.74%
Research Firm
4.62%
Venture Capital
3.66%
Corporation
1.33%
Endowment Fund
0.24%
Family Office
0.13%
Other
5.14%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
373
68.31M
94.93%
-22.23M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
2023Q1
342
70.12M
118.05%
-6.08M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Matrix Capital Management Company, LP
13.96M
19.4%
--
--
Mar 31, 2025
Walters (William T)
7.05M
9.8%
+3.05M
+76.25%
Jan 29, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.33%
-10.27K
-0.27%
Mar 31, 2025
The Vanguard Group, Inc.
3.26M
4.53%
-10.63K
-0.32%
Mar 31, 2025
Millennium Management LLC
3.07M
4.27%
-711.78K
-18.82%
Mar 31, 2025
Acadian Asset Management LLC
2.67M
3.72%
+1.61M
+150.56%
Mar 31, 2025
Decheng Capital LLC
2.02M
2.81%
-318.33K
-13.62%
Mar 31, 2025
Opaleye Management Inc.
1.99M
2.76%
+217.50K
+12.31%
Mar 31, 2025
Almitas Capital LLC
1.71M
2.38%
+84.03K
+5.16%
Mar 31, 2025
Tang Capital Management, LLC
1.50M
2.08%
+1.50M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Federated Hermes MDT Small Cap Core ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity Growth Opportunities ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Ver más
Federated Hermes MDT Small Cap Core ETF
Proporción0.07%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
iShares Micro-Cap ETF
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0%
Fidelity Growth Opportunities ETF
Proporción0%
T Rowe Price Small-Mid Cap ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
